👩🎓
Happy to share that NeuroSense Therapeutics has been granted the prestigious AAN Late Breaker slot. A heartfelt thank you to Prof. Merit Cudkowicz for presenting the outcomes of our Paradigm study! https://lnkd.in/d9yaaYzR
Skip to main content
👩🎓
Happy to share that NeuroSense Therapeutics has been granted the prestigious AAN Late Breaker slot. A heartfelt thank you to Prof. Merit Cudkowicz for presenting the outcomes of our Paradigm study! https://lnkd.in/d9yaaYzR
To view or add a comment, sign in
NeuroSense Therapeutics - Distinguished 12-month results from the PARADIGM ALS clinical trial https://lnkd.in/dAGwmb98
To view or add a comment, sign in
Today, we honor the legacy of Lou Gehrig, the legendary New York Yankees player who passed away on this day in 1941 due to #ALS. Gehrig not only made a lasting mark on baseball, but he also brought national attention to Amyotrophic Lateral Sclerosis. His courage and resilience in the face of ALS continues to inspire us. Let's take this day to remember his contributions and support those affected by ALS. Alone we are rare. Together we are strong 💪 #ALSAwareness #StrikeOutALS NeuroSense Therapeutics
To view or add a comment, sign in
As we at NeuroSense Therapeutics develop treatments for people living with ALS, we are well aware of the toll it takes. We are in awe of the inspiring and humbling story of Brian Wallach. Brian has been living with ALS since 2017 and has made it his mission to find hope for others. Thank you, Brian and Sandra Abrevaya, for giving us all a glimpse into the lives of people living with ALS. Your incredible dedication to keep looking forward is an inspiration to us all. On a personal note, it gives us the drive to work even harder at finding a cure and bringing effective therapies to people who suffer from ALS. Watch their journey and join the fight! #Love ❤️ #Determination 💪 #BetterTogether 👨👩👦👦 #ALS 🤛 https://lnkd.in/g-dYm5Vr
To view or add a comment, sign in
NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine Learning https://lnkd.in/dCZc5Gwc
NeuroSense Therapeutics Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine Learning This may lead to great outcomes, by increasing success rates in a pivotal trial. Thanks to Raviv Pryluk and the PhaseV team. https://lnkd.in/dVUZZ8wk
To view or add a comment, sign in
We are happy to share the Q1 updates. New Data from the PARADIGM trial to be shared soon. Stay Tuned 😊 https://lnkd.in/d2-zvV6N
To view or add a comment, sign in
May is ALS Awareness Month. At NeuroSense Therapeutics, every day and every hour is dedicated to battling this horrific disease. Our commitment is unwavering - there is only one path forward: to be determined, hopeful, and ultimately successful in our fight against ALS. Join us in making a difference. Together, we can change lives. https://lnkd.in/etzAnkwr
To view or add a comment, sign in
At NeuroSense Therapeutics, we remain dedicated and will make every effort to help those suffering from ALS maintain their freedom. We are not alone in this endeavor; we are pleased to collaborate with Genetika+ to advance our efforts and also support individuals affected by Alzheimer's disease. Special thanks to Talia Cohen Solal , Daphna Laifenfeld, David Pattison, CPA and the exceptional team at Genetika+ for their remarkable efforts and partnership. Thanks to the team at $NRSN who have advanced this collaboration, including Shiran Zimri, Niva Russek- Blum, Diana Shtossel, Hagit Binder and others. Onward and upward for a better future https://lnkd.in/dEu5q5WQ
To view or add a comment, sign in
Everybody knows the Ice Bucket Challenge. And now, Nas Daily, Nuseir Yassin came to visit and was impressed. Thank you Yassin for telling about how we at NeuroSense fight ALS, all with one tiny pill. Bill Gates, Elon Musk, Donald Trump and many others participated in the Ice Bucket Challenge and we are fortunate to present how it materialized. $NRSN https://lnkd.in/dCi9J8ij
To view or add a comment, sign in
Create your free account or sign in to continue your search
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now